Sellas Life Sciences Group Inc (SLS) Stock Price, Quote & News

Company Profile

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is adm...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 200 5278

Website: sellaslifesciences.com

Address:

7 Times Square, Suite 2503, New York, United States

BlakeCanyon50 May. 13 at 11:10 AM

$SLS Grandma is getting the upgrade wheelchair kit with hydraulics & nice rims. 🤓

0 · Reply

texmade2 May. 13 at 11:10 AM

$SLS nice

0 · Reply

EddieH2020 May. 13 at 11:08 AM

$SLS I feel sorry for all the people that didn’t full port here 🤣 must be stressful for them scalping 5-10% gains at other tickers and not bag holding lmaoooo 😜

0 · Reply

WhyMeWorry May. 13 at 11:08 AM

$SLS New 52 Week High Today! Let’s Go 👍⛽️🙏

0 · Reply

Lolichocho May. 13 at 11:07 AM

$SLS topped off this AM @ 6.04 for a nice even 5000. I had sold a bunch of $10 calls to straddle with my $2 and 2.5 call buys so I'll get nice $750 and $800 bonuses after we crack double digits, whenever that is...soon me thinks

0 · Reply

Lucci80 May. 13 at 11:05 AM

$SLS ALL YOU NEED TO KNOW, SEND IT!!!! https://www.linkedin.com/feed/update/activity:7460060578808487937?trk=viral_share

0 · Reply

Stonski May. 13 at 11:02 AM

$SLS we are ABSOLUTELY hitting $10 this week after yesterday earnings.. I think a lot of watchers and stutes that wanted a more realistic confirmation got it last night .. BUYS should be coming in aggressively!!

1 · Reply

Beroname May. 13 at 11:00 AM

$SLS fintel is blocking my ip....can someone check whats up with short shares ?

2 · Reply

Harsh1210 May. 13 at 11:00 AM

$SLS shorted more at 6.50 It's going pretty well as it will come under $5 cause of open and dilution Will open bigger position at open

2 · Reply

MrBlockchain May. 13 at 11:00 AM

$SLS Hey, anybody own any SLS? 😀

2 · Reply

Sellas Life Sciences options imply 4.6% move in share price post-earnings

May 12, 2026, 4:05 PM EDT - 15 hours ago

SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

2026-04-27T14:41:49.000Z - 15 days ago

Sellas Life Sciences call volume above normal and directionally bullish

Mar 27, 2026, 8:05 AM EDT - 6 weeks ago

These 16 stocks are a short seller's dream — likely losers no matter what the market does

EVCM LCID NNE SERV

2026-03-25T12:45:19.000Z - 6 weeks ago

Largest borrow rate increases among liquid names

DFDV INFY LABD SOUN UAMY

2026-03-20T21:05:42.000Z - 7 weeks ago

Sellas Life Sciences files automatic mixed securities shelf

2026-03-20T11:11:35.000Z - 7 weeks ago

Sellas Life Sciences price target raised to $10 from $7.50 at Alliance Global

Mar 19, 2026, 4:05 PM EDT - 7 weeks ago

SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update

2026-03-19T17:35:17.000Z - 7 weeks ago

Sellas Life Sciences options imply 6.2% move in share price post-earnings

2026-03-17T20:35:49.000Z - 2 months ago

Sellas Life Sciences to present preclinical SLS009 data at AACR conference

Mar 17, 2026, 4:30 PM EDT - 2 months ago

SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference

2026-03-12T13:00:19.000Z - 2 months ago

Sellas announces enrollment of first patient in Phase 2 SLS009 trial

Mar 12, 2026, 8:35 AM EDT - 2 months ago

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

2026-02-20T13:48:14.000Z - 2 months ago

Largest borrow rate increases among liquid names

DPRO HUMA PDYN SIDU USAS UVXY VELO

2026-01-22T22:00:18.000Z - 3 months ago

Mixed options sentiment in Sellas Life Sciences with shares down 1.75%

2026-01-14T13:37:03.000Z - 4 months ago

Sellas Life Sciences enters agreement with IMPACT-AML

Jan 14, 2026, 8:30 AM EST - 4 months ago

SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe

2025-12-31T14:40:20.000Z - 4 months ago

Unusually active option classes on open December 31st

BXSL DJT DOW NIO NKE NVDA ONDS

2025-12-31T13:45:13.000Z - 4 months ago

Largest borrow rate increases among liquid names

BTQ CIFR FJET GRRR IRE KDK PMCB

2025-12-29T14:40:17.000Z - 4 months ago

Unusually active option classes on open December 29th

HWM MS PAAS PBR SLV VZLA

Dec 29, 2025, 8:35 AM EST - 4 months ago

SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)

$SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025$

Dec 7, 2025, 6:00 PM EST - 5 months ago

SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025

Oct 29, 2025, 10:00 AM EDT - 6 months ago

SELLAS Life Sciences Group Transcript: R&D Day 2025

Oct 27, 2025, 8:30 AM EDT - 7 months ago

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds

Aug 7, 2025, 8:30 AM EDT - 9 months ago

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification

Jul 7, 2025, 8:45 AM EDT - 11 months ago

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

Jun 5, 2025, 8:45 AM EDT - 1 year ago

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

Jun 2, 2025, 8:00 AM EDT - 1 year ago

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

May 20, 2025, 8:00 AM EDT - 1 year ago

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

May 15, 2025, 8:45 AM EDT - 1 year ago

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 13, 2025, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 28, 2025, 8:45 AM EDT - 1 year ago

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

Apr 23, 2025, 10:23 AM EDT - 1 year ago

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 8, 2025, 8:45 AM EDT - 1 year ago

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

Mar 20, 2025, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

Feb 20, 2025, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

Jan 28, 2025, 3:11 PM EST - 1 year ago

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 23, 2025, 8:10 AM EST - 1 year ago

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Jan 8, 2025, 8:20 AM EST - 1 year ago

SELLAS Announces Key Business Objectives for 2025

Dec 10, 2024, 9:00 AM EST - 1 year ago

SELLAS Life Sciences Group Transcript: Study Update

Dec 10, 2024, 8:30 AM EST - 1 year ago

SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Dec 9, 2024, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML

Nov 27, 2024, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

Nov 13, 2024, 4:15 PM EST - 1 year ago

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 8:00 AM EST - 1 year ago

voxeljet, Dressler Group GmbH, Fraunhofer IPA and the University of Bayreuth Collaborate in Re-Processing of Discarded PA12 Powder for 3D Printing via High-Speed Sintering (HSS)

Nov 5, 2024, 9:55 AM EST - 1 year ago

SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024

Oct 15, 2024, 8:45 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

Oct 10, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Aug 13, 2024, 4:10 PM EDT - 1 year ago

SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 6, 2024, 8:45 AM EDT - 1 year ago

SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

Jul 16, 2024, 9:05 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia

Jul 8, 2024, 8:45 AM EDT - 2 years ago

SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia

Jun 24, 2024, 9:05 AM EDT - 2 years ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

Jun 17, 2024, 9:05 AM EDT - 2 years ago

SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia

Jun 10, 2024, 8:40 AM EDT - 2 years ago

SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML

May 14, 2024, 4:05 PM EDT - 2 years ago

SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 1, 2024, 8:35 AM EDT - 2 years ago

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

Apr 29, 2024, 8:45 AM EDT - 2 years ago

SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study

Mar 28, 2024, 4:05 PM EDT - 2 years ago

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 26, 2024, 8:15 AM EDT - 2 years ago

SELLAS Life Sciences Group Transcript: Study Update

Mar 26, 2024, 7:35 AM EDT - 2 years ago

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study

Mar 19, 2024, 4:05 PM EDT - 2 years ago

SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 19, 2024, 8:47 AM EDT - 2 years ago

SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET

Mar 15, 2024, 9:00 AM EDT - 2 years ago

SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 8, 2024, 8:00 AM EST - 2 years ago

SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships

Mar 1, 2024, 8:30 AM EST - 2 years ago

SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference

Feb 29, 2024, 8:00 AM EST - 2 years ago

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time

BlakeCanyon50 May. 13 at 11:10 AM

$SLS Grandma is getting the upgrade wheelchair kit with hydraulics & nice rims. 🤓

0 · Reply

texmade2 May. 13 at 11:10 AM

$SLS nice

0 · Reply

EddieH2020 May. 13 at 11:08 AM

$SLS I feel sorry for all the people that didn’t full port here 🤣 must be stressful for them scalping 5-10% gains at other tickers and not bag holding lmaoooo 😜

0 · Reply

WhyMeWorry May. 13 at 11:08 AM

$SLS New 52 Week High Today! Let’s Go 👍⛽️🙏

0 · Reply

Lolichocho May. 13 at 11:07 AM

0 · Reply

Lucci80 May. 13 at 11:05 AM

$SLS ALL YOU NEED TO KNOW, SEND IT!!!! https://www.linkedin.com/feed/update/activity:7460060578808487937?trk=viral_share

0 · Reply

Stonski May. 13 at 11:02 AM

1 · Reply

Beroname May. 13 at 11:00 AM

$SLS fintel is blocking my ip....can someone check whats up with short shares ?

2 · Reply

Harsh1210 May. 13 at 11:00 AM

$SLS shorted more at 6.50 It's going pretty well as it will come under $5 cause of open and dilution Will open bigger position at open

2 · Reply

MrBlockchain May. 13 at 11:00 AM

$SLS Hey, anybody own any SLS? 😀

2 · Reply

SoYeonPicks May. 13 at 11:00 AM

$SLS People talking about 5 or 6 or 7.. This is still a binary readout. Once we have the blowout top line, this is going beyond double digits.

1 · Reply

Bangerstocksbuyer May. 13 at 10:59 AM

$SLS Well fuck

1 · Reply

MrBlockchain May. 13 at 10:54 AM

$SLS There were some P R E T T Y BIG blocks traded last night at the ASK and it didn't make a dent in short interest. Watch for pull backs today and see how they are met. Till then, just say BOOM!!! Now my favorite GIF.

0 · Reply

Atomickb May. 13 at 10:52 AM

$SLS - hmm cannot hold 6.25 pre market . Needs short covering to power through 6.5 and 7. If not it may settle around 5.5 to 6 .

2 · Reply

Saltyfish87 May. 13 at 10:45 AM

$SLS volume will pick up soon. Watch the hour before open.

0 · Reply

Lttiller May. 13 at 10:45 AM

$SLS

0 · Reply

Rogerrabbit May. 13 at 10:44 AM

$SLS Well, Good Luck today longs, 78 events, god bless them all 🙏❤️ , DD and patience pays off, still cheap to buy more SLS 😎🏖💪👊

0 · Reply

Wayne07939 May. 13 at 10:44 AM

$SLS Remove the Stop Loss, turn off share lending. Squeeeeeeeeeeeeeeeeeze

0 · Reply

Flooringaem04 May. 13 at 10:42 AM

$SLS Premarket volume drying up. Opportunity for manipulators to push us down a few shares at a time. This will change big time at opening.

0 · Reply

jacckkmm May. 13 at 10:40 AM

$SLS With REGAL approaching its critical readout and SLS009 advancing across clinical and translational fronts, we believe that SELLAS is entering an exciting time with multiple, high-value potential catalysts that could transform the AML treatment landscape.” Got to love where we are now !

0 · Reply

isthisonebetter May. 13 at 10:39 AM

$SLS 🐢🇬🇷

0 · Reply

Saltyfish87 May. 13 at 10:36 AM

$SLS I forgot to mention…don’t waste your time trying to help them understand or correct what they will obviously get wrong. The DD is ours at this stage. If they are sincere they can go dig it up.

0 · Reply

Market Cap	968.80M
Revenue (ttm)	0.00
Net Income (ttm)	-26.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	5,782,300
Avg Vol	6,080,158
Day's Range	N/A - N/A
Shares Out	184.53M
Stochastic %K	74%
Beta	2.24
Analysts	Sell
Price Target	$10.00